A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
详细信息 查看全文
- 作者：Josep Marí ; a del Campoa ; jmcampof2@seom.org" class="auth_mail" title="E-mail the corresponding author ; Michael Birrerb ; mbirrer@mgh.harvard.edu" class="auth_mail" title="E-mail the corresponding author ; Craig Davisc ; craig.davis@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Keiichi Fujiwarad ; fujiwara@saitama-med.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Ashwin Gollerkerie ; ashwingollerkeri@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Martin Goref ; Martin.Gore@rmh.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; Brett Houkc ; Susie Laug ; susie.lau@mcgill.ca" class="auth_mail" title="E-mail the corresponding author ; Andres Povedah ; apoveda@fivo.org" class="auth_mail" title="E-mail the corresponding author ; Antonio Gonzá ; lez-Martí ; ni ; agonzalezm@seom.org" class="auth_mail" title="E-mail the corresponding author ; Carolyn Mullerj ; cmuller@salud.unm.edu" class="auth_mail" title="E-mail the corresponding author ; Kei Murok ; kmuro@aichi-cc.jp" class="auth_mail" title="E-mail the corresponding author ; Kristen Piercel ; kristen.j.pierce@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Mie Suzukim ; mie.suzuki@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Jennifer Vermetten ; jennifer.vermette@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Amit Ozao ; Amit.Oza@uhn.ca" class="auth_mail" title="E-mail the corresponding author
- 关键词：Endometrial cancer ; Gedatolisib ; mTOR ; PI3K ; Stathmin
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：142
- 期：1
- 页码：62-69
- 全文大小：499 K
文摘
- •
Two PI3K/mTOR inhibitors were evaluated in recurrent endometrial cancer patients.
- •
Gedatolisib demonstrated activity in stathmin-low expressing endometrial cancers.
- •
Appropriate biomarkers to direct gedatolisib therapy were not confirmed in the study.